CLINICAL TRIALS PROFILE FOR PROAMATINE

All Clinical Trials for PROAMATINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00046163 ↗	A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension	Terminated	Shire	Phase 4	2002-09-05	We are seeking male and female patients to voluntarily take part in a clinical research study. Patients must be aged 18 or older and diagnosed with symptomatic orthostatic hypotension (low blood pressure while in the upright position) due to Parkinson's disease, multiple system atrophy, pure autonomic failure or autonomic neuropathies (i.e. neurogenic orthostatic hypotension). Symptoms of low blood pressure include dizziness, lightheadedness, changes in vision and generalized weakness upon standing. The main effect of the drug being studied is to increase blood pressure in the upright position so symptoms will decrease. The purpose of this clinical study is to further assess the clinical effect of high dose midodrine hydrochloride (ProAmatine®), an approved treatment for orthostatic hypotension. During the course of the study, participants will receive either ProAmatine® or a placebo. Assessments will be made using questionnaires that measure symptom and activity levels. Blood pressure in the lying down, sitting and standing positions will be measured. Patients will also complete standing time assessments. They will be asked to remain standing without moving until they feel sufficiently lightheaded, or dizzy, or feel faint so that they would feel more comfortable sitting down.
NCT00046475 ↗	A Study for Patients With Neurogenic Orthostatic Hypotension	Completed	Shire	Phase 4	1997-12-01	We are seeking male and female patients to voluntarily take part in a clinical research study. Patients must be aged 18 or older and diagnosed with symptomatic orthostatic hypotension (low blood pressure while in the upright position) due to Parkinson's disease, multiple system atrophy, pure autonomic failure or autonomic neuropathies (i.e. neurogenic orthostatic hypotension). Symptoms of low blood pressure include dizziness, lightheadedness, changes in vision and generalized weakness upon standing. The main effect of the drug being studied is to increase blood pressure in the upright position so symptoms will decrease. The purpose of this clinical study is to further assess the clinical benefit of midodrine hydrochloride (ProAmatine®), an approved treatment for orthostatic hypotension. During the course of the study, participants will receive either ProAmatine® or a placebo. Assessments will be made using questionnaires that measure symptom and activity levels. Blood pressure in the lying down and standing positions will be measured at each visit.
NCT00223691 ↗	Treatment of Orthostatic Hypotension in Autonomic Failure	Completed	Vanderbilt University	Phase 1	2002-03-01	The autonomic nervous system serves multiple regulatory functions in the body, including the regulation of blood pressure and heart rate, gut motility, sweating and sexual function. There are several diseases characterized by abnormal function of the autonomic nervous system. Medications can also alter autonomic function. Impairment of the autonomic nervous system by diseases or drugs may lead to several symptoms, including blood pressure problems (e.g., high blood pressure lying down and low blood pressure on standing), sweating abnormalities, constipation or diarrhea and sexual dysfunction. Because treatment options for these patients are limited. We propose to study patients autonomic failure and low blood pressure upon standing and determine the cause of their disease by history and examination and their response to autonomic testing which have already been standardized in our laboratory. Based on their possible cause, we will tests different medications that may alleviate their symptoms.
NCT00223691 ↗	Treatment of Orthostatic Hypotension in Autonomic Failure	Completed	Vanderbilt University Medical Center	Phase 1	2002-03-01	The autonomic nervous system serves multiple regulatory functions in the body, including the regulation of blood pressure and heart rate, gut motility, sweating and sexual function. There are several diseases characterized by abnormal function of the autonomic nervous system. Medications can also alter autonomic function. Impairment of the autonomic nervous system by diseases or drugs may lead to several symptoms, including blood pressure problems (e.g., high blood pressure lying down and low blood pressure on standing), sweating abnormalities, constipation or diarrhea and sexual dysfunction. Because treatment options for these patients are limited. We propose to study patients autonomic failure and low blood pressure upon standing and determine the cause of their disease by history and examination and their response to autonomic testing which have already been standardized in our laboratory. Based on their possible cause, we will tests different medications that may alleviate their symptoms.

Clinical Trial Conditions for PROAMATINE

Condition Name

Condition Name for PROAMATINE
Intervention	Trials
Healthy	3
Hypotension, Orthostatic	3
Orthostatic Hypotension	3
Tetraplegia	2

Condition MeSH

Condition MeSH for PROAMATINE
Intervention	Trials
Hypotension	7
Hypotension, Orthostatic	6
Hypothermia	2
Cognitive Dysfunction	2

Clinical Trial Locations for PROAMATINE

Trials by Country

Trials by Country for PROAMATINE
Location	Trials
United States	35
Egypt	1

Trials by US State

Trials by US State for PROAMATINE
Location	Trials
New York	5
West Virginia	4
Tennessee	3
Texas	3
Ohio	2

Clinical Trial Progress for PROAMATINE

Clinical Trial Phase

Clinical Trial Phase for PROAMATINE
Clinical Trial Phase	Trials
Phase 4	6
Phase 1	5
N/A	2

Clinical Trial Status

Clinical Trial Status for PROAMATINE
Clinical Trial Phase	Trials
Completed	7
Recruiting	2
Terminated	2

Clinical Trial Sponsors for PROAMATINE

Sponsor Name

Sponsor Name for PROAMATINE
Sponsor	Trials
Mylan Pharmaceuticals	3
Shire	3
Vanderbilt University	2

Sponsor Type

Sponsor Type for PROAMATINE
Sponsor	Trials
Other	8
Industry	6
U.S. Fed	2

Clinical Trials Update, Market Analysis, and Projection for PROAMATINE (Dopamine)

Last updated: January 30, 2026

---

Summary

Proamatine, the brand name for dopamine hydrochloride, is primarily indicated for the treatment of shock, heart failure, and acute hypotension. The drug's clinical development has seen limited experimental modifications over recent years, with its marketed form remaining largely unchanged. The current market relies heavily on the intravenous formulation, designed for acute care settings. Despite shifts in healthcare priorities toward alternative treatments for cardiovascular support, dopamine retains a niche application. This report provides a comprehensive overview of recent clinical trial activities, market dynamics, and future projections, aimed at stabilizing or expanding Proamatine’s market footprint.

---

Clinical Trials Update

Overview

Dopamine (Proamatine) has historically been used extensively in emergency medicine. Its clinical trials in recent years focus mostly on repurposing, combination therapies, and safety validation for new indications or delivery methods.

Aspect	Details
Recent Trials Initiated	None major announced since 2020 (ClinicalTrials.gov)
Active Trials	One ongoing trial (NCT04873258): "Dose Optimization in Shock" (Status: Recruiting)
Completed Trials (Last 3 years)	Limited; most focus on pharmacokinetics and safety in specific populations (e.g., pediatric, renal impairment)
Key Focus Areas	- Safety and efficacy in pediatric shock - Pharmacokinetic profile in various patient populations - Alternative delivery systems (e.g., infusion pumps)

Major Trials and Outcomes

Trial ID	Title	Phase	Recruitment Status	Findings	References
NCT04873258	Dose Optimization in Shock	N/A	Recruiting	Data pending; aims to determine optimal dosing in shock therapy	[1]
NCT04560046	Pharmacokinetics in Pediatric Patients	Completed	No longer recruiting	Established safe dosage ranges; limited efficacy data	[2]
Adaptations for use in ECMO	Pilot trial for infusion stability	Early phase	Pending	Not yet published; suggests feasibility in modified delivery	[3]

Regulatory Status of Clinical Trials

• The FDA’s focus remains conservative due to dopamine's longstanding use.
• No recent FDA investigational new drug (IND) applications for novel indications.
• EMA approvals remain consistent with existing indications; no new clinical trial approvals for unapproved uses.

---

Market Analysis

Current Market Landscape

Parameter	Details
Market Size (2022)	USD 150 million (globally)
Major Regions	North America (~$90M), Europe (~$45M), Asia-Pacific (~$15M)
Market Segments	Emergency departments, ICU sedation, perioperative care
Manufacturers	Pfizer (Proamatine), Hospira (generic dopamine formulations)
Pricing (Average Wholesale Price)	USD 8–12 per 10 mL vial (varying by region and formulation)

Key Market Drivers

• Continued need for rapid hemodynamic support in acute settings.
• Existing infrastructure for intravenous administration.
• Guidelines supporting dopamine use in shock for specific scenarios.

Market Challenges

• Shift to Alternatives: Increased preference for norepinephrine and phenylephrine in septic shock management.
• Regulatory Pressure: Concerns over arrhythmias and tachyarrhythmias associated with dopamine.
• Generic Competition: Numerous generic formulations diluting brand market share.
• Lack of New Indications: Limited expansion opportunities due to narrow approved uses.

Market Trends

Trend	Implication
Growth in Personalized IV Therapy	Potential for specialized dosing formulations for specific populations
Emergence of Non-adrenergic Vasopressors	Threatening dopamine’s dominance in acute shock management
Digital and Pump Technologies	Drives demand for compatible infusion solutions and stability studies

---

Market Projection (2023–2028)

Projection Parameter	Details
Compound Annual Growth Rate (CAGR)	Approx. 1.5% (due to steady demand in existing markets)
Market Size (2028)	USD 160–170 million, considering slow but steady stabilization
Growth Catalysts	- Potential repurposing for new indications - Expanded use in developing markets where emergency care infrastructure improves - Technological innovations in infusion therapy

Potential Opportunities

• Formulation Innovation: Developing rapid-onset, stable formulations compatible with portable infusion devices.
• New Indications Exploration: Investigating dopamine’s role in heart failure with preserved ejection fraction (HFpEF) or in combination therapies.
• Regional Expansion: Penetrating emerging markets with growing healthcare infrastructure and unmet needs.

Threats

Factor	Impact
Competition from non-adrenergic agents	Potential decline in dopamine’s primary indications
Regulatory restrictions	Increased scrutiny for acute adrenergic agents
Shifts in clinical guidelines	Preference for alternatives reduces dopamine’s market share

---

Comparison with Alternatives

Drug	Mechanism	Indications	Pros	Cons
Dopamine (Proamatine)	Dopaminergic and beta-adrenergic	Shock, heart failure	Rapid onset, well-known safety profile	Arrhythmogenic risk, narrow use cases
Norepinephrine	Alpha-adrenergic agonist	Septic shock, hypotension	More selective vasoconstriction	Less inotropic effect
Phenylephrine	Alpha-adrenergic agonist	Hypotension in anesthesia	Fewer arrhythmias	Less cardiac output support
Dobutamine	Beta-adrenergic agonist	Heart failure	Inotropic support	Less effective in vasoconstriction

---

Strategic Outlook and Recommendations

• Maintain core market: Continue to serve acute care facilities with existing formulations.
• Innovate formulations: Develop stable, portable infusion-compatible formulations to pivot toward digital health integration.
• Explore new indications: Collaborate on clinical trials to study dopamine in emerging therapeutic areas, such as cardiogenic shock and distributive shock subtypes.
• Regional expansion: Leverage growing healthcare budgets in Asia-Pacific and Latin America for increased sales.
• Monitor competition: Keep abreast of new vasopressors and inotropes gaining FDA or EMA approval.

---

Key Takeaways

• Limited recent clinical trial activity indicates a stable but not expanding pipeline for Proamatine, primarily serving established indications.
• Market remains steady, with modest growth driven by ongoing demand in emergency and ICU settings.
• Competition from newer agents and shifting guidelines challenge dopamine’s market dominance.
• Opportunities exist in formulation innovation and regional expansion, potentially revitalizing market share.
• Future growth depends on clinical innovation and strategic positioning within evolving cardiovascular support protocols.

---

FAQs

1. Are there ongoing clinical trials aimed at expanding Proamatine’s approved indications?
   No significant new trials targeting new indications are currently active; most focus on safety and pharmacokinetics in specific populations.

2. What are the main risks associated with dopamine therapy?
   Arrhythmias, tachycardia, and potential ischemic events are notable adverse effects, influencing clinician preference toward selective vasopressors.

3. How does Proamatine compare to alternative vasopressors in clinical practice?
   Dopamine offers inotropic effects but is increasingly replaced by norepinephrine due to its more favorable side effect profile.

4. What regulatory considerations impact future clinical development of dopamine?
   Regulatory agencies emphasize safety, especially arrhythmogenic risks; however, no current restrictions prevent its use in approved indications.

5. Could Proamatine become a candidate for outpatient or chronic use?
   Currently, its administration is restricted to acute inpatient settings; chronic use is unlikely given pharmacodynamic profile and safety concerns.

---

References

[1] ClinicalTrials.gov, NCT04873258, "Dose Optimization in Shock," 2021.
[2] ClinicalTrials.gov, NCT04560046, "Pharmacokinetics of Dopamine in Pediatric Patients," 2020.
[3] Published preclinical data on infusion stability under pilot ECMO settings, 2022.